in vitro News and Research

RSS

Scientists identify digoxin as possible therapy for prostate cancer

Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.

4 Apr 2011

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers.

1 Apr 2011

USPTO issues patent to Asterand's BioMAP technology

Asterand plc, a leading provider of human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, and its subsidiary BioSeek LLC today announced that the United States Patent and Trademark Office has issued U.S. Patent Nos. 7,908,089 entitled "Patient classification" and 7,912,651 entitled "Function homology screening."

1 Apr 2011

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark Pharmaceuticals announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark's Biologics Research Centre located in Switzerland.

1 Apr 2011

mtm’s p16 and Ki-67 dual staining test identifies high-grade cervical disease in women with ASC-US and LSIL

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.

31 Mar 2011

KSB, SuperNova sign agreement to develop and commercialize Neopterin

SuperNova Diagnostics, a privately-held global diagnostics company for human and non-human health applications, announced today that it has signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology, a biotechnology diagnostics company specializing in research, manufacture and distribution of in-vitro diagnostic kits and research reagents in China and affiliated markets for the research, development, manufacture and commercialisation of diagnostic products and services for the measurement of Neopterin, its metabolites and derivatives utilising the SuperNova technology platform of AmpCrystal.

31 Mar 2011

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Eya1 protein phosphatase is a crucial regulator of the development of embryonic lung epithelial stem cells.

30 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

APC-300 drug significantly inhibits pancreatic cancer cell growth: Adamis

Adamis Pharmaceuticals Corporation announced today that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells.

25 Mar 2011

Mouse sperm created in lab: Hope for male infertility

In a scientific breakthrough, researchers report that they've grown mouse sperm from testicular tissue in the laboratory, a development that could advance the field of infertility in human males. Although still proven in mice, “this is a small but important step in understanding how sperm are formed, which may, in time, lead to us being able to grow human sperm in the laboratory,” said Dr. Allan Pacey, senior lecturer in andrology at the University of Sheffield in England, who is familiar with the study results.

24 Mar 2011

Contrast agent for tumor diagnostics

X-rays are not the only way: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. In the journal Angewandte Chemie, a team led by Wenbin Lin at the University of North Carolina (Chapel Hill, USA) has now introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal–organic coordination polymer, which allows an extraordinarily high level of dye loading.

23 Mar 2011

Researchers create nanosurfaces to seal leg prosthetics against bacteria entry

In recent years, researchers have worked to develop more flexible, functional prosthetics for soldiers returning home from battlefields in Afghanistan or Iraq with missing arms or legs. But even new prosthetics have trouble keeping bacteria from entering the body through the space where the device has been implanted.

23 Mar 2011

Rxi's new RNAi preclinical data to be presented at Keystone conference

RXi Pharmaceuticals Corporation, a recognized leader in RNA interference based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi compounds, including RXI-109, will be presented at the Keystone Symposia's Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

22 Mar 2011

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

China PharmaHub Corp., a biopharmaceutical acquisition and development company, today announced that it has signed a exclusive worldwide license agreement with the University of California, for worldwide rights to develop, commercialize and market a universal donor blood product derived from embryonic stem cells developed by UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa Carrier.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Roundup: Kan., Calif. budget cuts; Texas NICU costs; Katrina trial; Medco CalPERS contract 'dumped'

This list of programs cut in the California state budget includes a 10 percent reduction in what the state pays for Medi-Cal patients at all long-term care facilities $172.3 million and a 10 percent reduction in what the state pays to physicians who see people on Medi-Cal.

21 Mar 2011

Study on biodegradable tooth-binding micelles that inhibit Streptococcus mutans biofilm growth

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher F. Cheni will hold an oral presentation on a research study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans (S. mutans) Biofilm Growth."

21 Mar 2011

EDMA endorses the campaign against excessive use of salt

EDMA, the European Diagnostic Manufacturers Association, fully endorses the 2011 World Salt Awareness Week theme “Salt and Men’s Health” as the latter reminds that more men than women die prematurely of cardiovascular diseases (CVD).

21 Mar 2011

Tocopherol derivatives as new dioxin receptor antagonists

When reactive oxygen species (ROS) hit the body, vitamin E helps to prevent damage to tissues and cells by acting as an antioxidant. The health benefits of vitamin E are numerous, and in fact, studies have found that people with higher levels of vitamin E in their system have a lower risk of heart disease and certain forms of cancer. A team led by Thomas Rosenau from the University of Natural Resources and Life Sciences in Vienna (Austria) now describe their synthesis of a series of modified vitamin E derivatives that show promise as dioxin receptor antagonists in the European Journal of Organic Chemistry.

18 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011